Teva collaborates with Klinge, Formycon to commercialize biosimilar FYB203 in Europe and Israel

From Nasdaq.: 2025-01-13 01:27:11

Teva Pharmaceuticals International, a unit of Teva Pharmaceutical Industries, has partnered with Klinge Biopharma GmbH and Formycon AG to commercialize Formycon’s biosimilar candidate to Eylea, FYB203, in Europe (excluding Italy) and Israel. Teva will lead commercialization under the brand name AHZANTIVE3, while Klinge will receive milestone payments and a share of revenue. Klinge holds global commercialization rights to FYB203 from Formycon.

(Source: RTTNews)



Read more at Nasdaq.: Teva Collaborates With Klinge, Formycon For Semi-exclusive Commercialization Of FYB203